Developer docs
API playgroundTry for free, no card

Search company profiles

Excorp Medical

Full company profile

uuid000vkvs

Namestring
Excorp Medical
Legal namestring
Excorp Medical, Inc.
Websiteurl
excorp.com
Company typeenum
Private
Founded yearint
1995
Descriptiontext

Excorp Medical, Inc. is a private medical device company founded in 1995 and headquartered in Minneapolis, Minnesota, that has developed the Bioartificial Liver Support System (BLSS), an extracorporeal blood purification system intended to provide temporary metabolic support for patients in acute liver failure. The system continuously withdraws whole venous blood from the patient, regulates temperature, oxygenates to arterial levels, adjusts pH, and perfuses a hollow fiber bioreactor charged with approximately 100 grams of primary porcine hepatocytes before returning blood to the patient. The 100 kD nominal cutoff hollow fiber membrane serves as an immunoisolation barrier between species, allowing xenogeneic metabolic activity without direct blood contact. The platform technology is extendable beyond hepatocytes to pancreatic islets and other endocrine cell applications. Each therapeutic procedure is designed to last approximately 12 hours and may be repeated 2-3 times per liver failure episode.

The company targets liver transplant centers and academic medical centers in the US and Asia. The primary clinical use cases are bridging acute liver failure patients to native liver regeneration or to liver transplantation, with secondary use cases in post-liver-resection support and multi-organ failure scenarios. Phase I/II clinical trials have been completed at the University of Pittsburgh Medical Center under a 10-year collaboration with the Thomas E. Starzl Transplantation Institute, and the product has received FDA Orphan Drug Designation, providing seven-year market exclusivity upon approval. A planned Phase III trial has been described involving 150 patients across six US centers, but no FDA marketing approval or commercial sales have been disclosed.

The business model is enterprise field sales to hospitals, with revenue expected to be generated from sale of the BLSS device hardware and single-use bioreactor cartridges on a per-treatment basis, subject to hospital procurement and payer reimbursement. The company has established wholly owned subsidiaries in Hong Kong (Excorp Medical (HK), Ltd., 2008) and Wu'xi, China (Wu'Xi Excorp Biotech Co., Ltd., 2008), and is pursuing local manufacturing partnerships — including a planned joint venture with Shinva Medical Instrument in China and a manufacturing facility in Hyderabad, India — to localize bioreactor production for target markets. Revenue has not been publicly disclosed, and the company remains in pre-commercial clinical stage.

Short descriptiontext

Excorp Medical is a private Minneapolis-based medical device company developing the Bioartificial Liver Support System (BLSS), an extracorporeal hollow fiber bioreactor using primary porcine hepatocytes to provide temporary metabolic support for patients in acute liver failure. The FDA Orphan Drug-designated product is in pre-Phase III clinical development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMinneapolis, United States
HQ citystring
Minneapolis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bioartificial liver systems, extracorporeal liver support, hollow fiber bioreactor, xenogeneic cell therapy, acute liver failure devices
Industry2 codes
PRIMARYHLAKAEAB
Hepatology & Liver Disease
SECONDARYHLAKAEAK
Transplant Hepatology
Product category
Bioartificial Liver Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Bioartificial Liver System Products and Procedures
TypeHardware Sales
Description

Revenue generated from sale of the BLSS device and single-use bioreactor cartridges to hospitals and liver transplant centers. Treatments are expected to be 12 hours in duration and repeated 2-3 times during a given episode of liver failure, creating recurring revenue potential per patient episode.

excorp.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Excorp Medical develops and intends to commercialize the Bioartificial Liver Support System (BLSS), an extracorporeal medical device that continuously withdraws a patient's venous blood, oxygenates and conditions it, and perfuses a hollow fiber bioreactor charged with approximately 100 grams of primary porcine hepatocytes before returning the blood to the patient. The system is designed to provide temporary metabolic support for patients in acute liver failure until their own liver regenerates or until a liver transplant can be performed, with treatment sessions lasting approximately 12 hours and repeated 2-3 times per liver failure episode.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase I/II clinical trials completed demonstrating safety and proof of efficacy principle
+3 more records
Product overview1 text field

Excorp Medical is a medical device company with a single unified product offering: the Bioartificial Liver System (BLSS). The system is an extracorporeal liver assist device designed to provide temporary metabolic support for patients in acute liver failure until their own liver regenerates or until a liver transplant can be performed. The company operates through subsidiaries in China (Wu'xi Excorp Biotech Co., Ltd.) and Hong Kong (Excorp Medical (HK), Ltd.) for manufacturing and regional operations. The BLSS is protected by US and European patents and has received FDA Orphan Drug Designation.

Product and service1 record
1Bioartificial Liver Support System (BLSS)
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1ChinaBio Investor Forum
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2009-02-20
Description

Selected as 1 of 20 companies to present at ChinaBio Investor Forum 2009 in Hong Kong for investor outreach and partnership development.

excorp.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

10-year collaboration with the leading university in liver transplantation and tissue engineering for development of the Bioartificial Liver System. Dr. Jack Patzer serves as Principal Investigator and Coordinator of the Bioartificial Liver Program. Dr. George Mazariegos led preclinical studies and Phase I/II clinical trial evaluation.

3Hong Kong University Clinical Trials Centre
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership for protocol development and clinical trial operations in Hong Kong. Lead investigators selected and protocol development ongoing for Phase I/II clinical trials.

excorp.com
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Planned joint venture (Shinva Excorp Bioscience Corp., Ltd.) in Zibo, Shandong Province, China for manufacturing and distribution of bioartificial liver products in China.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research and academic partnership in Hong Kong for liver failure research and clinical development.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Excorp Medical (HK), Ltd. admitted to Hong Kong Science & Technology Parks in December 2008, providing access to infrastructure and biotech ecosystem support.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership announced in 4th quarter 2013 for animal biotechnology collaboration supporting bioartificial liver development.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Formal relationship announced in 3rd quarter 2013 for research collaboration in India.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
1Vital Therapies
TypeDirect peer
Description

Vital Therapies developed the ELAD (Extracorporeal Liver Assist Device) bioartificial liver system using human liver-derived cell lines (C3A). It was the most direct US competitor in bioartificial liver technology, though it ceased operations after Phase III failure in 2018, illustrating the difficulty of this therapeutic category.

TypeBroad incumbent
Description

Terumo BCT is a major supplier of blood component collection, processing, and cell therapy manufacturing systems. As an established extracorporeal blood processing technology provider, it represents both a potential supplier and a strategic partner or acquirer for cell-based liver support platforms.

TypeBroad incumbent
Description

Baxter markets the MARS (Molecular Adsorbent Recirculating System) albumin dialysis liver support therapy through its acquired Gambro business. MARS is the most clinically established non-cell-based extracorporeal liver support system and competes for the same hospital budget as Excorp's BLSS.

TypeEmerging player
Description

Miromatrix is developing bioengineered whole organs and tissues using its proprietary decellularization/recellularization platform, including liver applications. Its work on functional liver constructs is conceptually adjacent to Excorp's extracorporeal bioreactor approach.

TypeEmerging player
Description

Organovo is developing 3D-bioprinted human liver tissue for therapeutic and research applications, including potential use in liver disease and toxicity testing. While targeting a different technology modality, it represents an adjacent emerging approach to cell-based liver therapy.

TypeEmerging player
Description

Promethera develops liver-derived cell therapies (Heparesc and other allogeneic hepatic progenitor cell products) for liver disease, including acute and chronic indications. It represents an adjacent cell-therapy approach to addressing liver failure patients.

TypeBroad incumbent
Description

Fresenius developed and commercialized the Prometheus fractionated plasma separation and adsorption (FPSA) liver support system. As the global dialysis leader, Fresenius represents an entrenched incumbent in extracorporeal blood purification therapies and a potential strategic acquirer of cell-based alternatives.

8Cytonet
TypeEmerging player
Description

Cytonet (formerly known as Cytonet GmbH) developed cell-based liver therapies using isolated human liver cells for extracorporeal application in patients with acute liver failure. It is the closest European cell-based liver support peer to Excorp's approach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Excorp Medical

Bioartificial Liver Medical Devicesexcorp.com

Excorp Medical is a private Minneapolis-based medical device company developing the Bioartificial Liver Support System (BLSS), an extracorporeal hollow fiber bioreactor using primary porcine hepatocytes to provide temporary metabolic support for patients in acute liver failure. The FDA Orphan Drug-designated product is in pre-Phase III clinical development.

What Excorp Medical does

Excorp Medical, Inc. is a private medical device company founded in 1995 and headquartered in Minneapolis, Minnesota, that has developed the Bioartificial Liver Support System (BLSS), an extracorporeal blood purification system intended to provide temporary metabolic support for patients in acute liver failure. The system continuously withdraws whole venous blood from the patient, regulates temperature, oxygenates to arterial levels, adjusts pH, and perfuses a hollow fiber bioreactor charged with approximately 100 grams of primary porcine hepatocytes before returning blood to the patient. The 100 kD nominal cutoff hollow fiber membrane serves as an immunoisolation barrier between species, allowing xenogeneic metabolic activity without direct blood contact. The platform technology is extendable beyond hepatocytes to pancreatic islets and other endocrine cell applications. Each therapeutic procedure is designed to last approximately 12 hours and may be repeated 2-3 times per liver failure episode.

The company targets liver transplant centers and academic medical centers in the US and Asia. The primary clinical use cases are bridging acute liver failure patients to native liver regeneration or to liver transplantation, with secondary use cases in post-liver-resection support and multi-organ failure scenarios. Phase I/II clinical trials have been completed at the University of Pittsburgh Medical Center under a 10-year collaboration with the Thomas E. Starzl Transplantation Institute, and the product has received FDA Orphan Drug Designation, providing seven-year market exclusivity upon approval. A planned Phase III trial has been described involving 150 patients across six US centers, but no FDA marketing approval or commercial sales have been disclosed.

The business model is enterprise field sales to hospitals, with revenue expected to be generated from sale of the BLSS device hardware and single-use bioreactor cartridges on a per-treatment basis, subject to hospital procurement and payer reimbursement. The company has established wholly owned subsidiaries in Hong Kong (Excorp Medical (HK), Ltd., 2008) and Wu'xi, China (Wu'Xi Excorp Biotech Co., Ltd., 2008), and is pursuing local manufacturing partnerships — including a planned joint venture with Shinva Medical Instrument in China and a manufacturing facility in Hyderabad, India — to localize bioreactor production for target markets. Revenue has not been publicly disclosed, and the company remains in pre-commercial clinical stage.

Excorp Medical firmographics

Firmographics
Name
Excorp Medical
Legal name
Excorp Medical, Inc.
Website
https://excorp.com
Company type
Private
Founded year
1995
Operating status
Operating
Headcount range
11–50 employees
Short description
Excorp Medical is a private Minneapolis-based medical device company developing the Bioartificial Liver Support System (BLSS), an extracorporeal hollow fiber bioreactor using primary porcine hepatocytes to provide temporary metabolic support for patients in acute liver failure. The FDA Orphan Drug-designated product is in pre-Phase III clinical development.
Ownership category
akta.pro rank

Excorp Medical industry classification

Industry
Product category
Bioartificial Liver Medical Devices
akta.pro industry
PRIMARYHLAKAEAB
Hepatology & Liver Disease
SECONDARYHLAKAEAK
Transplant Hepatology

Keywords

  • Bioartificial liver systems
  • Extracorporeal liver support
  • Hollow fiber bioreactor
  • Xenogeneic cell therapy
  • Acute liver failure devices

Where Excorp Medical is headquartered

Location

Headquarters

HQ city
Minneapolis
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Excorp Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Supply Chain, Marketing or Sales

Revenue model

  1. Bioartificial Liver System Products and Procedures: Revenue generated from sale of the BLSS device and single-use bioreactor cartridges to hospitals and liver transplant centers. Treatments are expected to be 12 hours in duration and repeated 2-3 times during a given episode of liver failure, creating recurring revenue potential per patient episode.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Excorp Medical product offering

Product offering

Core offering

Excorp Medical develops and intends to commercialize the Bioartificial Liver Support System (BLSS), an extracorporeal medical device that continuously withdraws a patient's venous blood, oxygenates and conditions it, and perfuses a hollow fiber bioreactor charged with approximately 100 grams of primary porcine hepatocytes before returning the blood to the patient. The system is designed to provide temporary metabolic support for patients in acute liver failure until their own liver regenerates or until a liver transplant can be performed, with treatment sessions lasting approximately 12 hours and repeated 2-3 times per liver failure episode.

Product overview

Excorp Medical is a medical device company with a single unified product offering: the Bioartificial Liver System (BLSS). The system is an extracorporeal liver assist device designed to provide temporary metabolic support for patients in acute liver failure until their own liver regenerates or until a liver transplant can be performed. The company operates through subsidiaries in China (Wu'xi Excorp Biotech Co., Ltd.) and Hong Kong (Excorp Medical (HK), Ltd.) for manufacturing and regional operations. The BLSS is protected by US and European patents and has received FDA Orphan Drug Designation.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bioartificial Liver Support System (BLSS)

Quantifiable outcome

  • Phase I/II clinical trials completed demonstrating safety and proof of efficacy principle
  • +3 more outcomes

Companies that use Excorp Medical

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles1 record

Excorp Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Excorp Medical partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor, core and major.

  • ChinaBio Investor ForumminorGTM or Marketing Partner · 20 February 2009Selected as 1 of 20 companies to present at ChinaBio Investor Forum 2009 in Hong Kong for investor outreach and partnership development.
  • University of Pittsburgh - Thomas E. Starzl Transplantation InstitutecoreStrategic or Co-development Partner10-year collaboration with the leading university in liver transplantation and tissue engineering for development of the Bioartificial Liver System. Dr. Jack Patzer serves as Principal Investigator and Coordinator of the Bioartificial Liver Program. Dr. George Mazariegos led preclinical studies and Phase I/II clinical trial evaluation.
  • Hong Kong University Clinical Trials CentrecoreStrategic or Co-development PartnerPartnership for protocol development and clinical trial operations in Hong Kong. Lead investigators selected and protocol development ongoing for Phase I/II clinical trials.
  • Shinva Medical Instrument Co., Ltd (新华医疗器械股份有限公司)majorChannel Partner/ Reseller/ DistributorPlanned joint venture (Shinva Excorp Bioscience Corp., Ltd.) in Zibo, Shandong Province, China for manufacturing and distribution of bioartificial liver products in China.
  • The Chinese University of Hong KongminorStrategic or Co-development PartnerResearch and academic partnership in Hong Kong for liver failure research and clinical development.
  • Hong Kong Science & Technology ParksminorChannel Partner/ Reseller/ DistributorExcorp Medical (HK), Ltd. admitted to Hong Kong Science & Technology Parks in December 2008, providing access to infrastructure and biotech ecosystem support.
  • National Institute of Animal Biotechnology (India)minorStrategic or Co-development PartnerPartnership announced in 4th quarter 2013 for animal biotechnology collaboration supporting bioartificial liver development.
  • Acharya Nagarjuna University (India)minorStrategic or Co-development PartnerFormal relationship announced in 3rd quarter 2013 for research collaboration in India.

Scale indicators9 records

Recent moves11 records

Expansion highlights5 records

Excorp Medical competitors and assessment

Company assessment

Direct peers

  • Vital Therapies: Vital Therapies developed the ELAD (Extracorporeal Liver Assist Device) bioartificial liver system using human liver-derived cell lines (C3A). It was the most direct US competitor in bioartificial liver technology, though it ceased operations after Phase III failure in 2018, illustrating the difficulty of this therapeutic category.

Broad incumbents

  • Terumo BCT: Terumo BCT is a major supplier of blood component collection, processing, and cell therapy manufacturing systems. As an established extracorporeal blood processing technology provider, it represents both a potential supplier and a strategic partner or acquirer for cell-based liver support platforms.
  • Baxter International (MARS system): Baxter markets the MARS (Molecular Adsorbent Recirculating System) albumin dialysis liver support therapy through its acquired Gambro business. MARS is the most clinically established non-cell-based extracorporeal liver support system and competes for the same hospital budget as Excorp's BLSS.
  • Fresenius Medical Care (Prometheus system): Fresenius developed and commercialized the Prometheus fractionated plasma separation and adsorption (FPSA) liver support system. As the global dialysis leader, Fresenius represents an entrenched incumbent in extracorporeal blood purification therapies and a potential strategic acquirer of cell-based alternatives.

Emerging players

  • Miromatrix Medical: Miromatrix is developing bioengineered whole organs and tissues using its proprietary decellularization/recellularization platform, including liver applications. Its work on functional liver constructs is conceptually adjacent to Excorp's extracorporeal bioreactor approach.
  • Organovo: Organovo is developing 3D-bioprinted human liver tissue for therapeutic and research applications, including potential use in liver disease and toxicity testing. While targeting a different technology modality, it represents an adjacent emerging approach to cell-based liver therapy.
  • Promethera Biosciences: Promethera develops liver-derived cell therapies (Heparesc and other allogeneic hepatic progenitor cell products) for liver disease, including acute and chronic indications. It represents an adjacent cell-therapy approach to addressing liver failure patients.
  • Cytonet: Cytonet (formerly known as Cytonet GmbH) developed cell-based liver therapies using isolated human liver cells for extracorporeal application in patients with acute liver failure. It is the closest European cell-based liver support peer to Excorp's approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Excorp Medical social profiles

Digital presence

Excorp Medical compliance and trust

Trust signal

Compliance1 record

Excorp Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Excorp Medical leadership team

Management profile

Number of profiles

Profiles11 records

Excorp Medical subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Excorp Medical funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Excorp Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Excorp Medical

What does Excorp Medical do?

Excorp Medical develops and intends to commercialize the Bioartificial Liver Support System (BLSS), an extracorporeal medical device that continuously withdraws a patient's venous blood, oxygenates and conditions it, and perfuses a hollow fiber bioreactor charged with approximately 100 grams of primary porcine hepatocytes before returning the blood to the patient. The system is designed to provide temporary metabolic support for patients in acute liver failure until their own liver regenerates or until a liver transplant can be performed, with treatment sessions lasting approximately 12 hours and repeated 2-3 times per liver failure episode.

Is Excorp Medical a public or private company?

Excorp Medical is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Excorp Medical founded?

Excorp Medical was founded in 1995. It employs 11 to 50 people.

Where is Excorp Medical based?

Excorp Medical is headquartered in Minneapolis, United States, in the North America region.

How does Excorp Medical make money?

One revenue line is on record: bioartificial Liver System Products and Procedures.

Who are Excorp Medical's main competitors?

Vital Therapies is listed as a direct peer. Broad incumbents are Terumo BCT, Baxter International (MARS system) and Fresenius Medical Care (Prometheus system). Emerging players are Miromatrix Medical, Organovo, Promethera Biosciences and Cytonet.

Does Excorp Medical have an API?

No public API is recorded for Excorp Medical.

What industry is Excorp Medical in?

Excorp Medical's product category is Bioartificial Liver Medical Devices. Its primary akta.pro industry code is HLAKAEAB, Hepatology & Liver Disease, with a secondary code of HLAKAEAK, Transplant Hepatology.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales